The Leeds Teaching Hospitals NHS Trust


In clinical trials Riluzole has been shown to modestly slow down the progression of MND. NICE guidance recommends the use of Riluzole in the ALS subtype of MND. The medication should be initiated by a neurologist and close monitoring of potential side effects is required.

View Leeds Shared care guidelines for the use of Riluzole in MND

View NICE guidance on the use of Riluzole for the treatment of Motor Neurone Disease